Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials
Perspective Therapeutics (CATX) has reported encouraging early data from multiple radiopharmaceutical trials, highlighting progress in its 212Pb-based pipeline and expanding its reach into new indications like brain tumors. The company's theranostic approach shows promising results with favorable safety, tolerability, and improved tumor retention in ongoing Phase 1/2a studies for various solid tumors, including neuroendocrine tumors and melanoma. This progress strengthens the company's long-term growth narrative and its integrated manufacturing and direct-to-hospital delivery strategy.
Millennium (CATX) reports 4.89M shares (4.3%) in Perspective Therapeutics
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported shared voting and dispositive power over 4,893,883 shares (4.3%) of Perspective Therapeutics, Inc. in a SCHEDULE 13G filing. The filing indicates that while they acquired beneficial ownership above 5% on June 23, 2026, they ceased to be beneficial owners above that threshold by the filing date. This disclosure details their current ownership and confirms a joint filing agreement dated June 29, 2026.
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation
Perspective Therapeutics (CATX) updated its corporate presentation on July 1, 2026, focusing on next-generation 212Pb-based radiopharmaceuticals for oncology and an integrated production/delivery model. The presentation highlights a diverse pipeline targeting solid tumors, including VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α–expressing solid tumors, all currently in phase 1/2a trials. The company emphasizes a theranostic approach, regional manufacturing, and direct-to-hospital delivery to provide ready-to-administer products.
Price to sales forward of Perspective Therapeutics, Inc. – AMEX:CATX
This page provides information on the forward price-to-sales ratio for Perspective Therapeutics, Inc. (AMEX: CATX). It is a financial data point from TradingView, which aggregates market data from ICE Data Services and reference data from FactSet. The page itself is largely a placeholder, indicating where financial data would be displayed.
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX
The article focuses on the enterprise value to revenue forward metric for Perspective Therapeutics, Inc. (AMEX:CATX). It appears to be a financial data page from TradingView, displaying financial information for the company. The content primarily consists of navigation and branding elements inherent to the financial platform.
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX)
This article provides an overview of Perspective Therapeutics, Inc. (AMEX:CATX) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for income, balance sheet, cash flow, and valuation metrics, along with answers to frequently asked questions about the company's financials, earnings, and market capitalization. Investors are encouraged to conduct their own research, as the information is not investment advice.
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX
This article displays the "Price to earnings forward" metric for Perspective Therapeutics, Inc. (AMEX:CATX) on TradingView. It provides a placeholder for the period, value, and change of this financial metric, indicating that the specific data is "Made by humans" and will be updated. The piece is primarily a data placeholder within a financial platform, not a traditional report.
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis
Perspective Therapeutics Inc (CATX) has a financial score of 5.94, ranking 308 out of 389 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 77.78% year-over-year, and its net profit decreased by 44.08% year-over-year. Key financial metrics related to cash and cash equivalents, total assets, liabilities, free cash flow, operating profit, and income after tax have not yet been disclosed.
Perspective Therapeutics Inc (CATX) Institutional Confidence
Perspective Therapeutics Inc (CATX) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 54.19%, which is a 34.77% decrease quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 0.03% of shares outstanding.
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Perspective Therapeutics Inc (CATX), noting its current valuation score of 6.52, ranking it 328 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -2.11, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of dividend payouts and stock split events for Perspective Therapeutics Inc (CATX). It notes that CATX has distributed $0.00 in dividends over the past five years, indicating no recent dividend activity. The article also highlights a significant merger-related stock split event that occurred on April 9, 2024, at a 10-to-1 ratio.
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Perspective Therapeutics Inc (CATX), identifying its major shareholders and institutional holdings. It lists key corporate and investment entities like Lantheus Holdings, Inc. and Qatar Investment Authority, along with the proportion of shares they hold. The report also provides a historical overview of institutional shareholding data from Q1 2023 to Q1 2026, showing changes in the number of institutions and shares held over time.
Perspective Therapeutics Inc
This article provides a brief overview of Perspective Therapeutics Inc (CATX) focusing on its revenue breakdown. It highlights that relevant data for business segments and regional revenue by region have not yet been disclosed by the company, except for a United States revenue of $209.00K. The company's stock information, including market cap and recent price changes, is also presented.
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort
Perspective Therapeutics announced the dosing of the first meningioma patient in a Phase 1/2a study evaluating its targeted alpha-particle therapy, [212Pb]VMT-α-NET. This study is being conducted at the Heidelberg University Hospital and is focused on patients with somatostatin receptor expressing meningioma. The progression to dosing patients with meningioma follows prior enrollment of neuroendocrine tumor (NET) patients who showed positive safety and efficacy results in the Phase 1 trial.
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11
Wedbush has reiterated its Buy rating on Perspective Therapeutics (CATX.US) and maintained its price target of $11. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics has expanded its clinical trial for the experimental drug [212Pb]VMT-a-NET to include patients with meningioma, a common type of brain tumor. This Phase 1/2a study, named LEMONaDE, aims to evaluate the drug's safety and efficacy in patients with challenging-to-treat or recurrent SSTR2-positive meningiomas. The drug utilizes a radiopharmaceutical approach to target cancer cells directly, offering a new potential treatment option where few currently exist.
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics, Inc. has dosed the first meningioma patient with [212Pb]VMT-α-NET in its Phase 1/2a study, expanding its therapeutic focus beyond neuroendocrine tumors. This new cohort aims to assess the safety, dosimetry, and anti-tumor activity of its lead-based alpha-particle therapy for meningioma, recognizing that these common brain tumors consistently express SSTR2, making them an attractive target for this treatment.
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics has dosed the first brain tumor patient with its experimental drug [212Pb]VMT-a-NET in an expanded clinical trial. This trial now includes meningioma patients, the most common adult primary brain tumor, in addition to neuroendocrine tumors. The drug targets SSTR2-positive tumors to deliver concentrated radiation directly to cancer cells, addressing a critical need for effective treatments for aggressive or recurrent meningiomas.
Targeted alpha therapy trial doses first patient for common brain tumor
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the dosing of the first meningioma patient with [212Pb]VMT-α-NET in its Phase 1/2a LEMONαDE study. This new cohort aims to assess the safety, dosimetry, and preliminary anti-tumor activity of the alpha-particle therapy in SSTR2-expressing meningiomas, expanding the drug's development beyond neuroendocrine tumors. Meningiomas are the most common primary brain tumors in adults, and current treatment options are limited for patients with recurrent, progressive, or unresectable disease.
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
This article provides the transcript of Perspective Therapeutics Inc.'s presentation at the RBC Capital Markets Global Healthcare Conference held on May 19, 2026. The company was represented by its CFO, Joel, and head of IR, Annie. The transcript captures the initial greetings and appreciation for being invited to the conference.
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities
Bank of America Securities analyst Alec Stranahan has maintained a Hold rating on Perspective Therapeutics (CATX) with a price target of $6.00. This is despite a Strong Buy consensus among analysts, with an average price target of $12.82. The company recently reported a quarterly revenue of $76 thousand and a GAAP net loss of $26.19 million for the quarter ending March 31.
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment
Perspective Therapeutics is making significant progress in developing next-generation 212 Pb radiopharmaceuticals for solid tumor oncology, focusing on its proprietary approach to design, integrated isotope production, and a diverse pipeline including therapies for neuroendocrine tumors, melanoma, and FAP-α expressing solid tumors. The company highlights strong safety and efficacy data from its ongoing Phase 1/2a trials, particularly for VMT-α-NET, which supports potential registration studies. Its strategic advantages include a robust IP portfolio, regional manufacturing, and potential synergies with immune checkpoint inhibitors, positioning it for significant growth and impact on share value.
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update
Perspective Therapeutics (NYSE: CATX) filed an 8-K to update its corporate presentation, emphasizing its strategy for next-generation 212Pb radiopharmaceuticals to treat solid tumors. The company detailed three key programs: VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-ɑ in solid tumors, all currently in Phase 1/2a or early clinical trials. The presentation also highlighted integrated isotope production and direct-to-hospital delivery to ensure supply.
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy
Perspective Therapeutics (CATX) updated its corporate presentation, detailing advancements in its 212Pb-based oncology portfolio and regional isotope production strategies. The company highlighted ongoing Phase 1/2a trials showing preliminary anti-tumor activity and tolerability for several radiopharmaceuticals. Perspective emphasizes a direct-to-hospital delivery model for its regional isotope production and a strategic focus on IP coverage and a theranostic approach.
CATX - Perspective Therapeutics Inc Stock Price and Quote
This page provides comprehensive financial data and news for Perspective Therapeutics Inc. (CATX), including its stock price, market capitalization, key financial ratios, analyst ratings, and a chronological list of recent corporate announcements and news articles related to its clinical trials and business developments. The stock closed at $3.55, up 16.78%, with significant analyst coverage initiating and resuming ratings, mostly with 'Buy' or 'Overweight' recommendations and varying price targets.
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor
Shareholders of Perspective Therapeutics (NYSE: CATX) held their 2026 Annual Meeting, with 85.85% of shares represented. They re-elected six directors to the board and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, shareholders supported holding annual advisory votes on executive compensation.
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15
This article provides a brief overview of current analyst ratings for Perspective Therapeutics (CATX.US), indicating a forecast share price between $8 and $15. It would likely detail recent analyst actions and their implications for the stock's future performance.
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Piper Sandler analyst Biren Amin has reiterated a Buy rating for Perspective Therapeutics (CATX.US), maintaining the target price at $16. According to TipRanks data, the analyst has shown a 45.9% success rate and an average return of 8.8% over the past year. This rating is provided for informational purposes and is not investment advice.
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO
Perspective Therapeutics announced interim clinical results for its three 212Pb radiopharmaceutical programs which will be presented at the 2026 ASCO meeting. The data shows promising safety profiles with no dose-limiting toxicities across neuroendocrine tumors, metastatic melanoma, and FAP-positive solid tumors, alongside early signs of antitumor activity. The company plans to release further data updates in late 2026.
Early melanoma trial sees tumor responses in hard-to-treat patients
Perspective Therapeutics announced updated data from its clinical programs, including [212Pb]VMT01 for melanoma, highlighting two confirmed responses out of seven heavily pre-treated patients (29% response rate) in its 3.0 mCi monotherapy cohort. The company is also advancing [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for FAP-expressing solid tumors, with further data to be presented at the 2026 ASCO Annual Meeting. All three programs have demonstrated favorable safety profiles, with no dose-limiting toxicities reported.
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation
UBS has reiterated its Buy recommendation for Perspective Therapeutics (CATX). This continued endorsement by a major financial institution suggests a positive outlook on the company's stock performance. Investors and market watchers may view this as a signal of confidence in CATX's future prospects.
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics announced it will present updated data from all three of its clinical programs—[²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359—at the 2026 ASCO Annual Meeting. Key findings include a new responder in the [212Pb]VMT01 melanoma trial, progression to a higher dose cohort for [²¹²Pb]PSV359 in solid tumors, and consistent efficacy with deepening responses for [212Pb]VMT-α-NET in neuroendocrine tumors. All three programs continue to demonstrate good tolerability.
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation
UBS has reaffirmed its Buy rating on Perspective Therapeutics (CATX). The financial services firm has also maintained its price target for CATX. This indicates continued confidence in the company's stock performance.
CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX)
This article provides recent news and analysis for Perspective Therapeutics Inc. (NYSEARCA:CATX). It highlights the company's mixed Q1 2026 results, surpassing Q2 2025 revenue estimates, and plans to present new clinical data at the 2026 ASCO Annual Meeting. The article also mentions the dosing of first patients in new cohorts of two ongoing Phase 1/2a studies.
Perspective Therapeutics doses first patients in two trial cohorts
Perspective Therapeutics (CATX) has begun dosing patients in two new cohorts for its Phase 1/2a clinical trials, using its radiopharmaceutical treatments [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for solid tumors. The company is valued at $439 million and has seen its stock rise by nearly 69% in the past six months, though it faces negative free cash flow. RBC Capital, H.C. Wainwright, Jones Trading, and Truist Securities have maintained positive ratings on the stock, with price targets ranging from $12 to $18, anticipating further data releases later in the year.
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors
Perspective Therapeutics, Inc. has begun dosing patients in Phase 1/2a clinical studies for two radiopharmaceuticals, [212Pb]VMT-α-NET and [212Pb]PSV359, targeting neuroendocrine and solid tumors, respectively. The studies aim to assess the safety and efficacy of these alpha-emitting isotopes. The company is using a "theranostic" approach to personalize cancer treatment, with ongoing expansion of clinical programs and manufacturing capabilities.
Two cancer radiopharmaceuticals start dosing patients in early trials
Perspective Therapeutics (NYSE American: CATX) announced the dosing of the first patients in new cohorts for two Phase 1/2a studies involving cancer radiopharmaceuticals. One study focuses on [212Pb]VMT-α-NET for SSTR2+ neuroendocrine tumors, exploring a front-loaded 20 mCi regimen. The other is for [212Pb]PSV359 in FAP-α–expressing solid tumors, with patients receiving up to four 6.0 mCi doses every eight weeks following a safety review.
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics has announced the first patients have been dosed in new cohorts of two ongoing Phase 1/2a studies. These studies involve [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for solid tumors. The company is exploring optimized dosing regimens to improve response rates and tolerability while assessing safety and preliminary anti-tumor activity.
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX)
Morgan Stanley has filed an amendment to its Schedule 13G for Perspective Therapeutics (CATX), reporting a shared voting power of 2,930,734 shares and a shared dispositive power of 2,959,296 shares, amounting to a 2.6% stake in the company. The filing, dated May 12, 2026, explicitly states that Morgan Stanley has ceased to be the beneficial owner of more than five percent of CATX's securities. This indicates a reduction in their ownership interest below the 5% threshold required for certain reporting categories.
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics announced its business highlights and financial results for the first quarter of 2026, showcasing advancements in its clinical programs for neuroendocrine tumors, melanoma, and FAP-positive solid tumors. The company reported a strong financial position with approximately $271 million in cash, cash equivalents, and short-term investments as of March 31, 2026, projecting a cash runway into late 2027. Key developments include regulatory engagement expected for its lead program, VMT-α-NET, and progress in expanding manufacturing infrastructure, including the near completion of its Chicago facility.
Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0
The article focuses on the working capital per share of Perspective Therapeutics, Inc. (FWB:AAJ0) as listed on the Frankfurt Stock Exchange. It provides context for financial analysis within the healthcare technology sector. The information is presented by TradingView, sourcing data from ICE Data Services, FactSet, and Quartr for SEC filings.
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027
Perspective Therapeutics reported a net loss of $26.2 million for Q1 2026 but bolstered its cash reserves to $271 million following a $164 million underwritten offering in February. This financial position is expected to fund operations and clinical milestones through late 2027. The company is advancing three clinical-stage radiopharmaceutical programs and expanding its manufacturing capabilities, including a facility in Chicago set for completion in 2026.
Perspective Therapeutics 1Q Loss/Shr 25c >CATX
Perspective Therapeutics announced a first-quarter loss per share of 25 cents. Further financial details are expected to be provided in their official earnings report. This report is identified by the stock symbol CATX.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, translating to a loss of 25 cents per share. This performance exceeded Wall Street expectations, which had predicted a loss of 29 cents per share. The company, an isotope-based medical products maker, recorded revenue of $76,000 for the period.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, or 25 cents per share, which was better than the 29 cents per share loss anticipated by analysts. The Seattle-based medical products maker generated $76,000 in revenue during the period. These results were generated by Automated Insights using data from Zacks Investment Research.
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 2026 Earnings With EPS -0.25 Beating -0.31 and Revenue $0.08M Missing $0.14M?
Perspective Therapeutics (CATX) reported Q1 2026 GAAP EPS of -$0.25, beating estimates of -$0.31, though grant revenue of $0.08 million missed the estimated $0.14 million. The company strengthened its financial position with a February 2026 offering, increasing cash and short-term investments to $271 million, which supported accelerated R&D investments in its clinical programs. Despite progress in clinical trials and a solid balance sheet, CATX faces challenges common to early-stage radiopharmaceutical developers, including limited revenue generation and widening operating losses, with its GF Value currently not available and a GF Score of 39/100.
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Perspective Therapeutics, Inc. announced its earnings results for the first quarter ended March 31, 2026. The company reported a net loss of USD 26.19 million, an increase from USD 18.18 million in the prior year. Basic and diluted loss per share from continuing operations remained constant at USD 0.25 compared to the previous year.
Perspective Therapeutics: $271M cash to advance 3 cancer trials
Perspective Therapeutics (NYSE American: CATX) reported Q1 2026 results, highlighting $271 million in cash, equivalents, and short-term investments, which is expected to fund operations into late 2027. The company is advancing three clinical-stage 212Pb radiopharmaceutical programs (VMT-α-NET, VMT01, PSV359) with multiple data milestones anticipated in 2026, alongside expanding its manufacturing network. Despite an increase in R&D expenses and a wider net loss, a February underwritten offering provided $164 million in net proceeds, strengthening its financial position.
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report
Perspective Therapeutics, Inc. (CATX) reported a net loss of $26.2 million for Q1 2026, widening from $18.2 million a year prior, primarily due to increased research and development expenses as it advances its radiopharmaceutical pipeline. The company's cash and short-term investments totaled $270.9 million, bolstered by a $175.0 million offering in February 2026, which management expects to fund operations and clinical milestones into late 2027. Key clinical programs, including VMT-α-NET, VMT01, and PSV359, are progressing through Phase 1/2a trials, with ongoing investments in manufacturing infrastructure to support future commercial-scale production.
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics announced its business highlights and financial results for the first quarter of 2026. The company is advancing three clinical-stage oncology programs and expects multiple clinical catalysts throughout 2026. Financially, the company reported approximately $271 million in cash, cash equivalents, and short-term investments as of March 31, 2026, with a cash runway expected into late 2027.
